Abstract
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male fetus. In women, AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation. As the size of the residual follicular pool depends on the quantity of small antral follicles and declines over time, the serum AMH level in women follows a characteristic trajectory: a gradual decline throughout the reproductive years and a precipitous drop at menopause, becoming undetectable soon after. Thus, AMH is clinically useful as a screening tool for diminished ovarian reserve (Cui et al. in Fertil Steril 105(02):481–485, 2016). Perturbations in serum AMH are linked with a variety of pathological conditions, for instance, polycystic ovaries syndrome (PCOS), the pathophysiology likely being the excess follicles in this syndrome which produce increased amounts of AMH (Dumont et al. in Reprod Biol Endocrinol 13:137, 2015). AMH is also elevated in some ovarian tumors such as adult granulosa cell tumors, and it can be used as a tumor marker to gauge response to therapy and monitor for recurrence. Within the domain of assisted reproductive technology, serum AMH assays are widely used to derive prognostic information such as the chance of successful ovarian stimulation, subsequent embryo quality and even pregnancy rates. Finally, in the rapidly evolving field of oncofertility, serum AMH holds great promise as a predictor of ovarian reserve after completion of cancer therapy. Our aim is to put forth an in-depth review of the clinical applications of AMH in contemporary practice.
Similar content being viewed by others
References
Cui L, Qin Y, Gao X, et al. Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertil Steril. 2016;105(02):481–5.
Dumont A, Robin G, Catteau-Jonard S, et al. Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol. 2015;13:137.
La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(02):113–30.
Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(06):698–710.
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(02):129–40.
Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011;26(9):2353–62.
Tokura Y, Yoshino O, Ogura-Nose S, et al. The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment. J Assist Reprod Genet. 2013;30(6):821–5.
Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones. 2011;10(2):95–103.
Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014;12:26.
Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment anti-Müllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99:477–83.
Dunlop CE, Anderson RA. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas. 2015;80:245–50.
Decanter C, Cloquet M, Dassonneville A, et al. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. Reprod Biomed Online. 2018;36:711–8.
Cobo A, Garcia-Velasco JA, Coello A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105:755–64.
Sermondade N, Sonigo C, Sifer C, et al. Serum anti-Müllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation. Fertil Steril. 2019;111:357–62.
Fabbri R, Macciocca M, Melotti C, et al. Anti-Müllerian hormone as an ovarian reserve marker in young cancer women who undergo ovarian tissue cryopreservation. Future Oncol. 2014;10:1343–51.
Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–44.
L. Kalich-Philosoph, H. Roness, A. Carmely et al., “Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility,” Science Translational Medicine, vol. 5, no. 185, Article ID 185ra62, 2013.
Roness H, Spector I, Leichtmann-Bardoogo Y, et al. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet. 2019;36:1793–803.
Färkkilä A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors—a comparative study with inhibin B. Int J Cancer. 2015;137:1661–71.
Zhang T, Deng L, Xiong Q, et al. Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor. Oncol Lett. 2018;16(3):3260–6.
Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. Hum Reprod. 2014;29(4):791–801.
Bungum L, Franssohn F, Bungum M, et al. The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women. PLoS ONE. 2013;8(9), Article ID e68223
Lindhardt Johansen M, Hagen CP, Johannsen TH, et al. Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013;2013, Article ID 198698
Josso N, Rey RA, Picard JY. Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol. 2013;2013:674105.
Aksglaede L, Christiansen P, Sørensen K, et al. Serum concentrations of anti-Müllerian hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. Acta Paediatr Int J Paediatr. 2011;100(6):839–45.
Visser JA, Hokken-Koelega ACS, Zandwijken GRJ, et al. Anti-Mullerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. Hum Reprod. 2013;28(7):1899–907.
Bertone-Johnson ER, Manson JE, Purdue-Smithe AC, et al. Anti-Mullerian hormone levels and incidence of early natural menopause in a prospective study. Hum Reprod. 2018;33:1175–82.
Depmann M, Eijkemans MJ, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta-analysis. J Clin Endocrinol Metab. 2018;103:3593–600.
Gleicher N, Barad DH. Dehydroepisterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011;9:67.
Sing V, Thakur P, Agrawal S, et al. Role of DHEA in diminished ovarian reserve, systematic review. World J Pharmaceut Res. 2015;4:2488–507.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Laxmi Shrikhande is a Medical Director and Senior Consultant at Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, India. Bhushan Shrikhande is a Clinical Associate at Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, India. Aditya Shrikhande is a Research Associate at Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, India.
Rights and permissions
About this article
Cite this article
Shrikhande, L., Shrikhande, B. & Shrikhande, A. AMH and Its Clinical Implications. J Obstet Gynecol India 70, 337–341 (2020). https://doi.org/10.1007/s13224-020-01362-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13224-020-01362-0